

Nathan J Coffey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6899613/publications.pdf>

Version: 2024-02-01

17
papers

753
citations

687363
13
h-index

888059
17
g-index

17
all docs

17
docs citations

17
times ranked

1308
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB ₁ R) Receptor with Reduced Lipophilicity. Journal of Medicinal Chemistry, 2022, 65, 2374-2387.	6.4	6
2	Cholesterol as a modulator of cannabinoid receptor CB ₂ signaling. Scientific Reports, 2021, 11, 3706.	3.3	19
3	Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB ₁ R) Antagonist. ACS Pharmacology and Translational Science, 2021, 4, 1175-1187.	4.9	29
4	CB ₁ R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky-Pudlak syndrome. Clinical and Translational Medicine, 2021, 11, e471.	4.0	16
5	The Heterogeneity of Lipid Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2021, 1311, 39-56.	1.6	27
6	The key role of NLRP3 and STING in APOL1-associated podocytopathy. Journal of Clinical Investigation, 2021, 131, .	8.2	66
7	Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 178-190.	2.9	16
8	Targeting Peripheral CB ₁ Receptors Reduces Ethanol Intake via a Gut-Brain Axis. Cell Metabolism, 2019, 29, 1320-1333.e8.	16.2	42
9	Crystal Structure of the Human Cannabinoid Receptor CB ₂ . Cell, 2019, 176, 459-467.e13.	28.9	268
10	Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy. Diabetes, Obesity and Metabolism, 2018, 20, 698-708.	4.4	48
11	Synthesis of ¹³ C ₆ -labeled, dual-target inhibitor of cannabinoid-1 receptor (CB ₁ R) and inducible nitric oxide synthase (iNOS). Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 773-779.	1.0	5
12	The Heterogeneity of Lipid Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2018, 1063, 33-55.	1.6	60
13	Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB ₁ R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis. Journal of Medicinal Chemistry, 2017, 60, 1126-1141.	6.4	31
14	Synthesis of ¹³ C ₆ -labeled, dual-target inhibitor of cannabinoid-1 receptor (CB ₁ R) and inducible nitric oxide synthase (iNOS). Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 460-465.	1.0	5
15	Decreasing CB ₁ receptor signaling in Kupffer cells improves insulin sensitivity in obese mice. Molecular Metabolism, 2017, 6, 1517-1528.	6.5	30
16	Cannabinoid CB ₁ receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight, 2017, 2, .	5.0	59
17	Ephrin-A3 promotes and maintains slow muscle fiber identity during postnatal development and reinnervation. Journal of Cell Biology, 2015, 211, 1077-1091.	5.2	29